These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3238951)

  • 1. An example of anti-Yta demonstrating a change in its clinical significance.
    AuBuchon JP; Brightman A; Anderson HJ; Kim B
    Vox Sang; 1988; 55(3):171-5. PubMed ID: 3238951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 51Chromium survival of Yt(a+) red cells as a determinant of the in vivo significance of anti-Yta.
    Davey RJ; Simpkins SS
    Transfusion; 1981; 21(6):702-5. PubMed ID: 7314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo studies of the long-term 51Cr red cell survival of serologically incompatible red cell units.
    Baldwin ML; Ness PM; Barrasso C; Kickler TS; Drew H; Tsan MF; Shirey RS
    Transfusion; 1985; 25(1):34-8. PubMed ID: 3969699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Jka, -C, and -E in a single patient, initially demonstrable only by the manual hexadimethrine bromide (Polybrene) test, with incompatibilities confirmed by 51Cr-labeled red cell studies.
    Maynard BA; Smith DS; Farrar RP; Kraetsch RE; Chaplin H
    Transfusion; 1988; 28(4):302-6. PubMed ID: 3133842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinically significant erythrocyte antibody detectable only by 51Cr survival studies.
    Baldwin ML; Barrasso C; Ness PM; Garratty G
    Transfusion; 1983; 23(1):40-4. PubMed ID: 6402832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with anti-Cartwright (Yta).
    Mohandas K; Spivack M; Delehanty CL
    Transfusion; 1985; 25(4):381-4. PubMed ID: 4024238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term in vivo survival of Rh(D)-negative donor red cells in a patient with anti-LW.
    Chaplin H; Hunter VL; Rosche ME; Shirey RS
    Transfusion; 1985; 25(1):39-43. PubMed ID: 3918363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transfusion policy toward a patient with an anti-Cartwright antibody (anti-Yta)].
    Arriaga F; García R; Guinot M; de la Rubia J; García M; Bonanad S; Marty ML
    Sangre (Barc); 1993 Aug; 38(4):327-9. PubMed ID: 8235948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of anti-Yt(b). Report of a case using a 51chromium red cell survival study.
    Levy GJ; Selset G; McQuiston D; Nance SJ; Garratty G; Smith LE; Goldfinger D
    Transfusion; 1988; 28(3):265-7. PubMed ID: 3285526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical significance of anti-Ge in an untransfused man.
    Pearson HA; Richards VL; Wylie BR; Bruce D; Watt JM; Wilkie D; Kronenberg H
    Transfusion; 1991; 31(3):257-9. PubMed ID: 2003326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohematologic study and transfusion approach to patients with public antibodies].
    Solves P; de la Rubia J; Arriaga F; Cervera J; Arnao M; Carpio N; Marty ML
    Sangre (Barc); 1997 Feb; 42(1):25-9. PubMed ID: 9229799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically significant allo-anti-I in an I-negative patient with massive hemorrhage.
    Chaplin H; Hunter VL; Malecek AC; Kilzer P; Rosche ME
    Transfusion; 1986; 26(1):57-61. PubMed ID: 3946005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some observations on the Inb antigen and evidence that anti-Inb causes accelerated destruction of radiolabeled red cells.
    Ferguson DJ; Gaal HD
    Transfusion; 1988; 28(5):479-82. PubMed ID: 3420678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo survival of K:18 red cells in a recipient with anti-K18.
    Barrasso C; Baldwin ML; Drew H; Ness PM
    Transfusion; 1983; 23(3):258-9. PubMed ID: 6679384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Normal survival in vivo of Yt (a+) red blood cells in a patient with anti-Yta].
    Serrano J; Paniagua C; Sánchez Fayos J; Outeiriño J; Calabuig T; Escudero A
    Sangre (Barc); 1986; 31(6):768-71. PubMed ID: 3563836
    [No Abstract]   [Full Text] [Related]  

  • 16. Accelerated destruction of radiolabeled red cells due to anti-Coltonb.
    Dzik WH; Blank J
    Transfusion; 1986; 26(3):246-8. PubMed ID: 3705142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated immune red cell destruction in the absence of serologically detectable alloantibodies.
    Davey RJ; Gustafson M; Holland PV
    Transfusion; 1980; 20(3):348-53. PubMed ID: 6770508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient anti-Gya in an untransfused man. Serologic characteristics and cell survival study.
    Ellisor SS; Reid ME; Avoy DR; Toy PT; Mecoli J
    Transfusion; 1982; 22(2):166-8. PubMed ID: 7071923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of anti-Yta antibody in a Yt(a+) patient.
    Mazzi G; Raineri A; Santarossa L; De Roia D; Orazi BM
    Vox Sang; 1994; 66(2):130-2. PubMed ID: 8184594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A second example of anti-Yta with rapid in vivo destruction of Yt(a plus) red cells.
    Göbel U; Drescher KH; Pöttgen W; Lehr HJ
    Vox Sang; 1974; 27(2):171-5. PubMed ID: 4850290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.